Kornimate/medical-research-clean huggingface dataset:
biomarkers in blood samples from young patients with newly diagnosed brain tumors undergoing standard radiation therapy and chemotherapy

Conditions: Brain and Central Nervous System Tumors

Summary: rationale: studying samples of blood in the laboratory from patients receiving radiation therapy and chemotherapy may help doctors learn more about the effects of this treatment on cells. it may also help doctors understand how well patients respond to treatment. purpose: this research study is studying biomarkers in blood samples from young patients with newly diagnosed brain tumors undergoing standard radiation therapy and chemotherapy.

objectives: primary * evaluate the fraction of peripherally circulating t-regulatory cells (t_regs) in pediatric patients with newly diagnosed medulloblastoma and compare it to the levels found in a control group of patients undergoing craniectomy for chiari malformation. * evaluate the longitudinal effects of standard radiotherapy and chemotherapy regimens on the overall population of lymphocytes as well as the fraction of t_reg cells in patients with medulloblastoma. secondary * determine the baseline fraction of t_reg cells in those with non-medulloblastoma posterior fossa tumors compared to levels found in patients undergoing decompression for chiari malformation. outline: this is a multicenter study. patients with chiari malformation and patients with posterior fossa tumor undergo standard surgery. patients with posterior fossa tumor also receive standard radiotherapy and chemotherapy. blood samples are collected at baseline and periodically to measure the level of circulating t-regulatory cells.

Eligibility criteria:
disease characteristics: * meets 1 of the following criteria: * histologically confirmed posterior fossa tumor * newly diagnosed disease * medulloblastoma or non-medulloblastoma (pilocytic astrocytoma, ependymoma, atypical rhabdoid tumor, or others) * scheduled to undergo craniotomy and tumor resection * chiari malformation * requires craniectomy for decompression * no secondary decompression patient characteristics: * no unexplained febrile illness * no active infection * no autoimmune disorders such as inflammatory bowel disease, juvenile rheumatoid arthritis, or systemic lupus erythematosus * no other immunosuppressive disorders (e.g., hiv infection) prior concurrent therapy: * see disease characteristics

Keywords: untreated childhood medulloblastoma untreated childhood cerebellar astrocytoma untreated childhood cerebral astrocytoma untreated childhood brain stem glioma childhood medulloepithelioma childhood infratentorial ependymoma newly diagnosed childhood ependymoma childhood atypical teratoid/rhabdoid tumor
maternal and newborn safety profile of progestogens in early pregnancy

Conditions: Early Pregnancy Bleeding; Recurrent Pregnancy Loss

Summary: this multinational, prospective, active surveillance, registry study following two cohorts will include study participants who are pregnant and seeking any type of medical treatment, including dydrogesterone and other progestogens, for either (a) recurrent pregnancy loss and/or bleeding in early pregnancy or (b) as in-vitro fertilization (ivf)/assissted reproductive technology (art) support. pregnant women not taking progestogen and are advised an alternative non-medical treatment, in the context of bleeding in early pregnancy, recurrent pregnancy loss, or undergoing natural cycle frozen embryo transfer (nc-fet) can also be included in this study. eligible study participants will be recruited via an international network of prescribing health care practitioners (hcps) in china, turkey, and russia with the aim to collect data related to maternal safety and newborn safety in women prescribed progestogens during early pregnancy. study participants will be followed from early pregnancy until 6 - 12 weeks after giving birth. all malformations will be captured via direct contacts with the study participants. study participants will be sent online questionnaires via the electronic patient reported outcomes (epro) solution provided by medidata. major malformations reported by the study participants will be validated by zeg berlin via relevant source documents and if necessary, via contacting the treating hcps. the total study duration is planned for approximately 4 years including recruitment and follow-up.


Eligibility criteria:
inclusion criteria: * pregnant women who wish to sustain their pregnancy * women who have tested positive (blood or urine) for pregnancy in the first trimester * treated with progestogens or any alternative treatment for early bleeding in pregnancy with evidence of an intrauterine pregnancy / unexplained recurrent or pregnancy loss (with ≥ 2 previous pregnancy losses) with evidence of an intrauterine pregnancy or having undergone ivf/ art embryo transfer and taking progestogen for luteal phase support (lps), with evidence of an intrauterine pregnancy * signed informed consent, allowing consent to contact all treating, or diagnosing hcp * able and willing to read and comprehend written instructions; comprehend and complete the questionnaires required by the protocol exclusion criteria: * serious disease or disease requiring teratogenic treatment (e.g., lupus erythematosus, multiple sclerosis, cancer) * multifetal pregnancy * more than four (4) previous ivf embryo transfers * previous exposure to dydrogesterone in index pregnancy * documented substance abuse * treatment with hormones which are known to cause malformations * participation in an observational study that might, in the recruiting hcp's opinion, influence the assessment for the current study * participation in a randomized clinical trial in the last 3 months * previous enrollment in the pearly study
effects of tofacitinib (cp-690,550) on magnetic resonance imaging (mri)- assessed joint structure in early rheumatoid arthritis (ra)

Conditions: Rheumatoid Arthritis

Summary: evaluation of efficacy and safety of tofacitinib (cp-690,550) for the treatment of early rheumatoid arthritis in adult patients with moderate to severe disease who are methotrexate naïve. the efficacy will be evaluated by exploring the effects on joint structure assessed by magnetic resonance imaging, x-rays and by standard clinical assessment.


Eligibility criteria:
inclusion criteria: * adult patients with moderate to severe early rheumatoid arthritis (\< 2 years) who are methotrexate and biologic disease modifying antirheumatic drug naive. exclusion criteria: * pregnant or lactating patients; * patients with renal or hepatic impairment or other severe or progressing disease; * patients with contraindication to magnetic resonance imaging with gadolinium contrast.

Keywords: early rheumatoid arthritis joint structure magnetic resonance imaging janus kinase (jak) inhibitor tasocitinib tofacitinib
efficacy of arthrocentesis by injection of ringer with or without corticosteroid in treatment of internal derangement

Conditions: Temporomandibular Joint Dysfunction; Pain; Arthrocentesis

Summary: the study aims to evaluate effectiveness of ringer injection with or without corticosteroid during arthrocentesis of the temporomandibular joint in the treatment of internal derangement of the temporomandibular joint (tmj).

this prospective clinical study was approved by local ethical committee and written informed consent will be obtained before the trial starts. criteria for selection of the patients was based on history and clinical findings characteristic of internal derangement. all these patients were initially treated with nsaids for 1 week and occlusal splints for 1 month had failed to respond to these conservative treatments. the patients with systemic problems which affect bone and joints,psychological problems ,history of maxillofacial fractures and orthognathic surgery were excluded from the study. a total of 60 patients with tmj internal derangement with failed conservative management, were subjected to tmj arthrocentesis. all arthrocentesis were performed by the same maxillofacial surgeon. subjects were randomly allocated into two groups (30 cases in each group). subjects in the group 1 received irrigation with ringer solution and in the group 2 ,subjects underwent irrigation with ringer solution with corticosteroid (dexamethasone ) .two examiners evaluated temporomandibular disorder's signs ( mouth opening,click , crepitus and pain) before, one month and 6 months after arthrocentesis.

Eligibility criteria:
inclusion criteria: * patients with clinical findings characteristic of internal derangement(clicking and joint pain lasting for more than 6 months) unilaterally or bilaterally and history of previous conservative drug therapy (nsaids and muscle relaxant ),splint therapy and physiotherapy without improvement. * patients of both sexes between 15 to 80 year's old * patients who are willing for evaluation in 1 and 6 months after arthrocentesis * patients who are provided written consent form exclusion criteria: * patient had systemic problems which affect bone and joints disease * patient with psychological problems * patient with history of maxillofacial fractures and orthognathic * patients who can not continue the study for private or social reasons

Keywords: internal derangement,arthrocentesis,corticosteroid
monitoring strategies for the detection of atrial fibrillation in patients with cryptogenic stroke

Conditions: Stroke; Atrial Fibrillation

Summary: randomized clinical trial comparing two monitoring strategies, the use of a 48-hour holter (routine care branch) and an event recorder for 7 days (intervention branch). patients admitted for cryptogenic stroke will be included. enrollment and randomization of patients will be carried out during the index case hospitalization, while follow-up will be done on an outpatient basis until day 7.

once the diagnose of cryptogenic stroke have been carried out, informed consent will be taken and participants will be randomized to 48-hour monitoring arm or 7-day monitoring arm, followed by discharge from hospital.

Eligibility criteria:
inclusion criteria: * all patients who have studies that classify stroke or tia as cryptogenic and who can carry out monitoring for 48 hours or 7 days will be included. * age ≥ 18 years exclusion criteria * history of atrial fibrillation (or atrial flutter) documented. * patients who already have an event recorder in place, permanent pacemaker, or implantable cardioverter-defibrillator * evidence of lacunar infarction. * hemorrhagic stroke * patient for palliative care
validation and turkish cross-cultural adaptation of treatment expectation questionnaire (tex-q) tool

Conditions: Physiotherapy Patients

Summary: the general treatment expectations of patients play a significant role in determining the outcomes of the different treatments they undergo. when it comes to physiotherapy programs, these expectations act as non-specific treatment components, capable of triggering subjective psychological changes and eliciting mechanisms that resemble placebo effects. when theory-based, multidimensional measurement tools that evaluate patients' expectations from various treatments are examined, the treatment expectation questionnaire (tex-q) questionnaire stands out. the aim of this study is to ensure the validity and reliability of the turkish version of this form, which can be answered by every patient receiving various treatments, as an objective alternative and to be included among other treatment expectancy measurement tools.

this study includes the translation of the form after obtaining the relevant permissions, examining the internal consistency of the turkish version, explanatory and confirmatory factor analysis, convergent validity and test-retest reliability processes. the turkish version of tex-q was applied to 200 patients who applied to the clinic for physiotherapy in the examination of internal consistency and exploratory factor analysis of the questionnaire. for convergent validity, 46 independent participants answered the turkish version of the tex-q, the positivity scale, and the hospital anxiety and depression scale. the test-retest reliability within a 2-weeks interval was analysed in 63 of patients seeking physiotherapy program.

Eligibility criteria:
inclusion criteria: * ages between 18-65 * who would receive physiotherapy for at least 2 weeks for any indication exclusion criteria: * insufficient level of turkish * having any mental problems that would prevent participation in the study * receiving another applied treatment other than the physiotherapy program

Keywords: patient expectation validity reliability
efficacy and safety of asf1057 in the treatment of seborrhoeic dermatitis

Conditions: Seborrheic Dermatitis

Summary: a growing body of evidence supports the hypothesis that the pathophysiology of seborrhoeic dermatitis has a potentially causative neurogenic inflammatory aspect. asf1057 is a new drug that acts through a modulation of neurogenic inflammation through important complementary mechanisms of action. this study will test the efficacy and safety of asf1057 in the treatment of patients with seborrhoeic dermatitis.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of moderate to severe seborrhoeic dermatitis exclusion criteria: * other active skin diseases * use of certain systemic and topical treatments * extensive sun exposure

Keywords: seborrhoeic dermatitis
neoadjuvant haic for resectable hepatocellular carcinoma beyond milan criteria

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this study is to evaluate the efficacy and safety of resection plus neoadjuvant hepatic arterial infusion chemotherapy (haic) compared with resection alone in patients with resectable hepatocellular carcinoma beyond milan criteria.

resection is the long-term therapeutic option for resectable hepatocellular carcinoma (hcc) patients. while a number of studies demonstrate poor effect and high relapse rate of resection for patients with resectable hepatocellular carcinoma beyond milan criteria. our previous prospective study also revealed that neoadjuvant transarterial chemoembolization (tace) seems to confer a survival benefit for resectable hcc. recently, the results of our previous prospective study suggested that, compared with tace, hepatic arterial infusion chemotherapy (haic) may improve the survivals for hcc with large hcc.thus, the investigators carried out this prospective randomized control to demonstrate the superiority of resection plus neoadjuvant haic over resection alone.

Eligibility criteria:
inclusion criteria: * the diagnosis of hcc was based on the diagnostic criteria for hcc used by the european association for the study of the liver (easl; * tumor burden beyond milan criteria * diagnosed as resectable with consensus by the panel of liver surgery experts; * no past history of resection, radiofrequency ablation, tace, tai, chemotherapy or molecule-targeted treatment; * no cirrhosis or cirrhotic status of child-pugh class a only; * meet the following laboratory parameters:(a) platelet count ≥ 75,000/μl; (b)hemoglobin ≥ 8.5 g/dl;(c) total bilirubin ≤ 30mmol/l;(d) serum albumin ≥ 32 g/l;(e) asl and ast ≤ 6 x upper limit of normal;(f) serum creatinine ≤ 1.5 x upper limit of normal;(g) inr \> 2.3 or pt/aptt within normal limits; (h) absolute neutrophil count (anc) \>1,500/mm3; * ability to understand the protocol and to agree to and sign a written informed consent document. exclusion criteria; * patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry. * known of serious heart disease which can nor endure the treatment such as cardiac ventricular arrhythmias requiring anti-arrhythmic therapy * evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy * known history of hiv * history of organ allograft * known or suspected allergy to the investigational agents or any agent given in association with this trial. * evidence of bleeding diathesis. * any other hemorrhage/bleeding event \> ctcae grade 3 * serious non-healing wound, ulcer, or bone fracture * known central nervous system tumors including metastatic brain disease * poor compliance that can not comply with the course of treatment and follow up.

Keywords: neoadjuvant hepatic arterial infusion chemotherapy bclc a/b folfox resection
predicting the risk of ovarian cancer recurrence using circulating tumor dna to assess residual disease

Conditions: Epithelial Ovarian Cancer

Summary: blood samples and tumor tissue will be collected at certain timepoints and will be tested.

blood samples will be tested by natera to identify residual tumor dna for genetic changes in the tumor to potentially improve prediction of long term prognosis and guide treatment options.

Eligibility criteria:
inclusion criteria: clinical diagnosis of epithelial ovarian cancer stage ii-iv exclusion criteria: insufficient tumor to perform signatera testing; inability to provide consent for the trial
metastatic colorectal cancer liver metastases outcomes after resin 90y microsphere radioembolization in the usa evaluation project

Conditions: Colorectal Cancer; Liver Metastases

Summary: investigator initiated multi-institutional retrospective review of clinical and radiographic outcomes after 90y resin microsphere radioembolization for metastatic colorectal liver metastases in the usa. the target is for at least 1,000 evaluable patients with 12+ weeks follow up.

investigator initiated multi-institutional retrospective review of clinical and radiographic outcomes after 90y resin microsphere radioembolization for metastatic colorectal liver metastases in the usa. the target is for at least 1,000 evaluable patients with 12+ weeks follow up. objectives: independent data collection and reporting of pre treatment and 12 week post treatment clinical, radiographic and radiation parameters and outcomes in patients treated in the usa from 2002-2010. data beyond 12 weeks will be collected and highly desirable, however as a minimum all patients will have 12 week follow up.

Eligibility criteria:
inclusion criteria: * patients who received 90y resin microsphere radioembolization for metastatic colorectal cancer with liver metastases between november 2010 and march 2011 in the usa. patients must have at least 12 weeks of follow up. exclusion criteria: * patients who received glass 90y microsphere radioembolization for metastatic colorectal liver metastases.

Keywords: metastatic colorectal cancer liver metastases 90y resin microsphere radioembolization retrospective data analysis
evaluation of safety, tolerability, immunogenicity and efficacy of a novel method in specific immunotherapy in cat allergic patients: a placebo controlled trial

Conditions: Allergy to Cat Dander

Summary: this study is placebo controlled, double blind, randomised, two arm dose escalation of a new product for specific immunotherapy in cat allergic patients


Eligibility criteria:
inclusion criteria: * history and subjective symptoms of cat dander allergy including cat specific allergic rhinitis * age 18 to 65 years * positive reaction to at least one concentration of cat dander allergen in skin prick test, intradermal provocation test and nasal provocation test exclusion criteria: * chronic infectious disease * acute infections * episode of non-allergic rhinitis within the last 4 weeks * use of allergen known to predict anaphylactic reactions * treatment with any other investigational drug within 3 months before trial entry * vaccination within the last week * nasal surgery within the last 8 weeks * progressive fatal disease * drug or alcohol abuse within the last 5 years * cat ownership * a history of significant cardiac insufficiency (nyha stage iii-iv) * coexisting severe disease, e.g. cardiovascular diseases * acute or history of obstructive respiratory insufficiency ( fev1 \<70%) * hepatic insufficiency * relevant anaemia (as judged by investigator) * blood donation within the last 30 days or intended blood donation (during the study or 30 days after participation) * pregnancy or breast feeding * sexually active woman of childbearing potential not actively practicing birth control by using a medically accepted device or therapy * lack of compliance or other sililar reason, that the investigator believes, precludes satisfactory participation in the study * systemic glucocorticoid therapy * allergic asthma and chronic medication with steroids at doses exceeding 200ug/day treatment with atii antagonists, b-blocker, ace inhibitors
a trial of the alk grass tablet in subjects with hayfever

Conditions: Allergy

Summary: this trial is performed to assess the efficacy and safety of the alk grass tablet for treatment of grass pollen induced rhinoconjunctivitis (hayfever).


Eligibility criteria:
eligibility criteria: * a history of grass pollen induced rhinoconjunctivitis * positive skin prick test to grass * positive specific ige to grass

Keywords: grass pollen allergy hayfever allergen immunotherapy specific immunotherapy
a study of tas-114 in combination with s-1 in patients with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: this is a phase 1 study of tas-114 in combination with s-1 in patients with advanced solid tumors.

this is a phase 1, open-label, non-randomized, dose-escalating safety, tolerability, and pharmacokinetic study of tas-114 in combination with s-1 in patients with advanced solid tumors.

Eligibility criteria:
inclusion criteria: * life expectancy of at least 3 months * histological or cytological documentation of advanced solid tumors * ecog performance status of ≤ 1 (ecog: eastern cooperative oncology group) * adequate bone marrow, liver and renal function * women of childbearing potential and men must agree to use adequate contraception
the relation between thyroid , parathyroid hormones and egfr in ckd patients in assiut

Conditions: Thyroid; Parathyroid Diseases; CKD

Summary: to evaluate the relation between thyroid, parathyroid hormones and estimated glomerular filtration rate in chronic kidney disease .

ckd is defined as abnormalities of kidney structure or function, present for \>3 months, with implications for health. ckd is classified based on cause, gfr category (g1-g5), and albuminuria category (a1-a3) . the global prevalence of ckd is 13.4%, with 10.6% being stages 3-5 ,over the past 10 years, the death rate due to ckd has increased by 31.7% . ckd patients remain sometimes asymptomatic, presenting the complications typical of renal dysfunction only in more advanced stages. its treatment can be conservative usually in patients with glomerular filtration rate above 15 ml/minute without indications of dialysis or replacement therapy . in ckd patients the changes of endocrine system levels may arise from several causes as the kidney is the site of degradation \& synthesis of many different hormones . so thyroid and parathyroid hormones dysfunction has been recognized as common co-morbidity that is often diagnosed with ckd . thyroid hormone is one of the most important hormones in the human body as it regulates majority of the body's physiological actions . parathyroid hormone (pth) is one of the most important hormones required for the maintenance of calcium and phosphate homeostasis . chronic kidney disease metabolic bone disorder (ckd-mbd) among patients with end stage renal disease ranges from 33% to 67%, and its severity tends to increase with the progression of the kidney damage \& high mortality rates . ckd-mbd causes bone abnormalities that affect turnover, volume, mineralization, vascular, linear growth, and density, and soft tissue calcification .

Eligibility criteria:
inclusion criteria: * 1. ckd patients 2. age (18-80 years) 3. diabetic nephropathy 4. hypertensive nephropathy 5. chronic pyelonephritis 6. obstructive nephropathy 7. polycystic kidney 8. gout nephropathy 9. nephrosclerosis exclusion criteria: * 1. patients underage of 18 and above 80 2. patients with history of thyroidectomy and parathyroidectomy 3. patients with history of thyroid and parathyroid disease before diagnosis of ckd 4. malignancy

Keywords: thyroid parathyroid diseases ckd